"Basal'' breast cancers are dominating the breast research literature at present and pathologists are under increasing pressure to evaluate for such a phenotype by their surgical and oncological colleagues. There is also much confusion about how to assess cancers, which immunohistochemical markers to use, what meaning and benefit this provides, and what the surgeons and oncologists will do with the information. Much remains to be done to answer all these questions but here we try to shed light on some of the issues and suggest what is still to com
Gene expression profiling of breast cancer delineates a particularly aggressive subtype referred to ...
Purpose: Breast carcinomas expressing basal epithelium cytokeratins constitute a tumor subgroup that...
The genomic subtyping of breast cancers into luminal A, luminal B, human epidermal growth factor rec...
It has been proposed that gene expression profiles will revolutionize the classification of breast c...
Introduction: Breast carcinomas are heterogeneous disease with different prognosis and therapy respo...
OBJECTIVE. Basal phenotype has been found to be an independent poor prognostic factor for breast can...
Breast cancer is a heterogeneous disease comprising five major subtypes including luminal A, luminal...
Breast cancer is a heterogeneous disease encompassing a variety of entities with distinct morphologi...
Human breast cancers referred to as "basal-like" are of interest because they lack effective therapi...
Aims: Recently, an immunohistochemical panel comprising antibodies against HER2, oestrogen receptor ...
Recent publications have classified breast cancers on the basis of expression of cytokeratin-5 and -...
peer reviewedThe breast pathology includes a large array of entities for which macroscopic and micro...
Breast carcinoma is a heterogeneous disease. It can be classified into phenotypes based on the expre...
Aims: There is a high frequency of serous gynaecological and basal breast cancers in patients with g...
Background: Grade-III invasive ductal carcinomas of no special type (IDCs-NST) constitute a heteroge...
Gene expression profiling of breast cancer delineates a particularly aggressive subtype referred to ...
Purpose: Breast carcinomas expressing basal epithelium cytokeratins constitute a tumor subgroup that...
The genomic subtyping of breast cancers into luminal A, luminal B, human epidermal growth factor rec...
It has been proposed that gene expression profiles will revolutionize the classification of breast c...
Introduction: Breast carcinomas are heterogeneous disease with different prognosis and therapy respo...
OBJECTIVE. Basal phenotype has been found to be an independent poor prognostic factor for breast can...
Breast cancer is a heterogeneous disease comprising five major subtypes including luminal A, luminal...
Breast cancer is a heterogeneous disease encompassing a variety of entities with distinct morphologi...
Human breast cancers referred to as "basal-like" are of interest because they lack effective therapi...
Aims: Recently, an immunohistochemical panel comprising antibodies against HER2, oestrogen receptor ...
Recent publications have classified breast cancers on the basis of expression of cytokeratin-5 and -...
peer reviewedThe breast pathology includes a large array of entities for which macroscopic and micro...
Breast carcinoma is a heterogeneous disease. It can be classified into phenotypes based on the expre...
Aims: There is a high frequency of serous gynaecological and basal breast cancers in patients with g...
Background: Grade-III invasive ductal carcinomas of no special type (IDCs-NST) constitute a heteroge...
Gene expression profiling of breast cancer delineates a particularly aggressive subtype referred to ...
Purpose: Breast carcinomas expressing basal epithelium cytokeratins constitute a tumor subgroup that...
The genomic subtyping of breast cancers into luminal A, luminal B, human epidermal growth factor rec...